Cellectar Biosciences Net Worth
Cellectar Biosciences Net Worth Breakdown | CLRB |
Cellectar Biosciences Net Worth Analysis
Cellectar Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cellectar Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cellectar Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cellectar Biosciences' net worth analysis. One common approach is to calculate Cellectar Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cellectar Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cellectar Biosciences' net worth. This approach calculates the present value of Cellectar Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cellectar Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cellectar Biosciences' net worth. This involves comparing Cellectar Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cellectar Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Cellectar Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cellectar Biosciences' net worth research are outlined below:
| Cellectar Biosciences generated a negative expected return over the last 90 days | |
| Cellectar Biosciences may become a speculative penny stock | |
| Net Loss for the year was (37.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cellectar Biosciences currently holds about 24.81 M in cash with (32.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cellectar Biosciences has a poor financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Cellectar Biosciences, Inc. Q3 2024 Earnings Call Transcript |
Cellectar Biosciences Quarterly Good Will |
|
Cellectar Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cellectar Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cellectar Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cellectar Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cellectar Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cellectar Biosciences backward and forwards among themselves. Cellectar Biosciences' institutional investor refers to the entity that pools money to purchase Cellectar Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-06-30 | 63.1 K | Northern Trust Corp | 2024-09-30 | 61.1 K | Xtx Topco Ltd | 2024-09-30 | 53 K | Jpmorgan Chase & Co | 2024-06-30 | 51.1 K | Susquehanna International Group, Llp | 2024-06-30 | 45.8 K | Millennium Management Llc | 2024-06-30 | 42.6 K | Jane Street Group Llc | 2024-06-30 | 41.9 K | Goldman Sachs Group Inc | 2024-06-30 | 35 K | Tower Research Capital Llc | 2024-06-30 | 31.8 K | Rosalind Advisors, Inc. | 2024-09-30 | 3.7 M | Aigh Capital Management, Llc | 2024-09-30 | 3.2 M |
Follow Cellectar Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.21 M.Market Cap |
|
Project Cellectar Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.15) | (2.99) | |
| Return On Capital Employed | 45.20 | 47.46 | |
| Return On Assets | (3.15) | (2.99) | |
| Return On Equity | 28.01 | 29.41 |
When accessing Cellectar Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cellectar Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cellectar Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Cellectar Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cellectar Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cellectar Biosciences' management manipulating its earnings.
Evaluate Cellectar Biosciences' management efficiency
Cellectar Biosciences has return on total asset (ROA) of (1.66) % which means that it has lost $1.66 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.9667) %, meaning that it created substantial loss on money invested by shareholders. Cellectar Biosciences' management efficiency ratios could be used to measure how well Cellectar Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At present, Cellectar Biosciences' Return On Capital Employed is projected to increase significantly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 29.41, whereas Return On Tangible Assets are projected to grow to (2.99). At present, Cellectar Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2 M, whereas Non Currrent Assets Other are forecasted to decline to about 28.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.11) | (0.12) | |
| Tangible Book Value Per Share | (0.11) | (0.12) | |
| Enterprise Value Over EBITDA | (0.64) | (0.67) | |
| Price Book Value Ratio | (24.97) | (23.72) | |
| Enterprise Value Multiple | (0.64) | (0.67) | |
| Price Fair Value | (24.97) | (23.72) | |
| Enterprise Value | 24.8 M | 26.1 M |
The strategic initiatives led by Cellectar Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (7.97) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cellectar Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cellectar Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cellectar Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jarrod Longcor over two months ago Acquisition by Jarrod Longcor of 450000 shares of Cellectar Biosciences at 1.74 subject to Rule 16b-3 | ||
Chanan-khan Asher over three months ago Acquisition by Chanan-khan Asher of 7800 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
Chanan-khan Asher over three months ago Acquisition by Chanan-khan Asher of 60000 shares of Cellectar Biosciences at 2.58 subject to Rule 16b-3 | ||
Darrell Lea over six months ago Acquisition by Darrell Lea of 100000 shares of Cellectar Biosciences at 1.68 subject to Rule 16b-3 | ||
James Caruso over six months ago Acquisition by James Caruso of 40596 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
John Neis over six months ago Acquisition by John Neis of 25000 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
Stefan Loren over a year ago Acquisition by Stefan Loren of 25000 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
Shustov Andrei over a year ago Cellectar Biosciences exotic insider transaction detected |
Cellectar Biosciences Earnings per Share Projection vs Actual
Cellectar Biosciences Corporate Management
| CPA CPA | CFO Sec | Profile | |
| Andrei MD | Senior Medical | Profile | |
| Shane Lea | Chief Officer | Profile | |
| Darrell Lea | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.